69.40
-0.40 (-0.57%)
| Penutupan Terdahulu | 69.80 |
| Buka | 68.78 |
| Jumlah Dagangan | 1,885,189 |
| Purata Dagangan (3B) | 2,065,345 |
| Modal Pasaran | 13,369,910,272 |
| Harga / Pendapatan (P/E TTM) | 771.11 |
| Harga / Pendapatan (P/E Ke hadapan) | 11.07 |
| Harga / Jualan (P/S) | 3.64 |
| Harga / Buku (P/B) | 4.19 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 11 Feb 2025 - 17 Feb 2025 |
| Margin Keuntungan | 0.80% |
| Margin Operasi (TTM) | 14.96% |
| EPS Cair (TTM) | 0.090 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 23.80% |
| Pertumbuhan Pendapatan Suku Tahunan (YOY) | -37.80% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1.15% |
| Nisbah Semasa (MRQ) | 1.87 |
| Aliran Tunai Operasi (OCF TTM) | 101.85 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 482.47 M |
| Pulangan Atas Aset (ROA TTM) | -0.12% |
| Pulangan Atas Ekuiti (ROE TTM) | 0.80% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Incyte Corporation | Menaik | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | -3.5 |
| Volatiliti Harga | -3.5 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -0.5 |
| Purata | -0.70 |
|
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Mid Core |
| % Dimiliki oleh Orang Dalam | 2.04% |
| % Dimiliki oleh Institusi | 97.71% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 97.00 (Citigroup, 39.77%) | Beli |
| Median | 72.50 (4.47%) | |
| Rendah | 52.00 (BMO Capital, -25.07%) | Jual |
| Purata | 75.20 (8.36%) | |
| Jumlah | 3 Beli, 6 Pegang, 1 Jual | |
| Harga Purata @ Panggilan | 72.45 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Wells Fargo | 19 Dec 2024 | 70.00 (0.86%) | Pegang | 67.06 |
| 30 Oct 2024 | 68.00 (-2.02%) | Pegang | 73.93 | |
| UBS | 17 Dec 2024 | 77.00 (10.95%) | Pegang | 69.40 |
| RBC Capital | 19 Nov 2024 | 74.00 (6.63%) | Pegang | 70.56 |
| 14 Nov 2024 | 80.00 (15.27%) | Pegang | 77.73 | |
| B of A Securities | 30 Oct 2024 | 90.00 (29.68%) | Beli | 73.93 |
| BMO Capital | 30 Oct 2024 | 52.00 (-25.07%) | Jual | 73.93 |
| Citigroup | 30 Oct 2024 | 97.00 (39.77%) | Beli | 73.93 |
| Goldman Sachs | 30 Oct 2024 | 70.00 (0.86%) | Pegang | 73.93 |
| JP Morgan | 30 Oct 2024 | 71.00 (2.31%) | Pegang | 73.93 |
| 23 Oct 2024 | 65.00 (-6.34%) | Pegang | 65.17 | |
| Morgan Stanley | 30 Oct 2024 | 69.00 (-0.58%) | Pegang | 73.93 |
| Oppenheimer | 30 Oct 2024 | 82.00 (18.16%) | Beli | 73.93 |
| Papar semua | ||||
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| FLANNELLY BARRY P | - | 72.11 | -1,510 | -108,886 |
| SWAIN PAULA J | - | 72.11 | -873 | -62,952 |
| TRAY THOMAS | - | 69.18 | -1,300 | -89,928 |
| Jumlah Keseluruhan Kuantiti Bersih | -3,683 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -261,766 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 70.64 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| TRAY THOMAS | Pegawai | 16 Dec 2024 | Jual (-) | 650 | 69.80 | 45,370 |
| TRAY THOMAS | Pegawai | 13 Dec 2024 | Jual (-) | 650 | 68.55 | 44,558 |
| FLANNELLY BARRY P | Pegawai | 09 Dec 2024 | Dibuang (-) | 1,510 | 72.11 | 108,886 |
| SWAIN PAULA J | Pegawai | 09 Dec 2024 | Dibuang (-) | 873 | 72.11 | 62,952 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2024 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |